Beneficial effects of clopidogrel on glycemic indices and oxidative stress in patients with type 2 diabetes

Abstract Objective of present study is to evaluate the possible role of clopidogrel in improving gly- cemic indices and oxidative stress in patients with type 2 diabetes. This study was performed on 42 uncontrolled type 2 diabetic patients at the specialized center for Endocrinology and Diabetes, Al-Rasafa Directorate of Health, Baghdad. All of the patients were treated with (glibenclamide 5 mg at morning) and randomized into two groups: the first group includes 22 patients treated with clopidogrel tablets (75 mg/day) for 2 months; the second group includes 20 patients treated with a placebo formula (sodium bicarbonate 200 mg/day) for the same period. Treatment with clopidogrel produced significant improvement (P 0.05) in fasting serum glucose (FSG), fasting serum insulin level, quantitative insulin sensitivity check index (QUICKI); and oxidative stress markers: serum malondialdehyde (MDA) and serum reduced glutathione (GSH) compared to their baseline levels. There was significant elevation (P 0.05) in both FSG and fasting serum insulin and the MDA level with significant reduction (P 0.05) in QUICKI of placebo group compared to their baseline levels. However, clopidogrel produced significant ele- vation (P 0.05) in AST and ALT levels but placebo formula caused no significant alteration (P 0.05) in the serum levels of these two enzymes. In conclusion the treatment with clopidogrel improved glycemic indices and reduced oxidative stress in patients with type 2 diabetes.